Zinc transporter 8 autoantibodies: what is their clinical relevance in gestational diabetes?
OBJECTIVE
To investigate the prevalence, clinical significance and antepartum to postpartum trajectory of zinc transporter 8 autoantibodies, a novel marker of islet autoimmunity, in women with gestational diabetes mellitus.


METHODS
A total of 302 consecutive women attending a multi-ethnic Australian gestational diabetes clinic were prospectively studied. Zinc transporter 8 autoantibodies were measured at gestational diabetes diagnosis and 3 months postpartum using an enzyme-linked immunosorbent assay, and were correlated with maternal phenotype, antepartum and postpartum glucose tolerance, treatment and perinatal outcomes.


RESULTS
Of the 302 women, 30 (9.9%) were positive for one islet autoantibody antepartum. No participant had multiple islet autoantibodies. Zinc transporter 8 autoantibodies were the most prevalent autoantibody [zinc transporter 8 autoantibodies: 13/271 women (4.8%); glutamic acid decarboxylase 7/302 women (2.3%); insulinoma-associated antigen-2: 6/302 women (2.0%); insulin: 4/302 women (1.3%)]. Zinc transporter 8 autoantibody positivity was associated with a higher fasting glucose level on the antepartum oral glucose tolerance test, but not with BMI, insulin use, perinatal outcomes or postpartum glucose intolerance. Five of the six women who tested positive for zinc transporter 8 autoantibodies antepartum were negative for zinc transporter 8 autoantibodies postpartum, which corresponded to a significant decline in titre antepartum to postpartum (26.5 to 3.8 U/ml; P=0.03). This was in contrast to the antepartum to postpartum trajectory of the other islet autoantibodies, which remained unchanged.


CONCLUSIONS
Zinc transporter 8 autoantibodies were the most common islet autoantibody in gestational diabetes. Zinc transporter 8 autoantibody positivity was associated with slightly higher fasting glucose levels and, unlike other islet autoantibodies, titres declined postpartum. Zinc transporter 8 autoantibodies may be a marker for islet autoimmunity in a proportion of women with gestational diabetes, but the clinical relevance of zinc transporter 8 autoantibodies in pregnancy and gestational diabetes requires further investigation.
Discipline of Medicine, The University of Sydney, Sydney, Australia; Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia; Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, Australia.
V L
VL
Rudland
C
C
Pech
A J
AJ
Harding
K
K
Tan
K
K
Lee
L
L
Molyneaux
D K
DK
Yue
J
J
Wong
G P
GP
Ross
D000328:Adult; D001315:Australia; D001323:Autoantibodies / Q000097:blood*; D015551:Autoimmunity / Q000502:physiology*; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D015992:Body Mass Index; D027682:Cation Transport Proteins / Q000276:immunology*; D016640:Diabetes, Gestational / Q000188:drug therapy / Q000276:immunology* / Q000503:physiopathology; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000276:immunology*; D049590:Postpartum Period / Q000097:blood / Q000276:immunology; D011247:Pregnancy; D011446:Prospective Studies; D000075703:Zinc Transporter 8
D001323:Autoantibodies; D015415:Biomarkers; D001786:Blood Glucose; D027682:Cation Transport Proteins; D007328:Insulin; C492522:SLC30A8 protein, human; D000075703:Zinc Transporter 8